Ownership
Private
Employees
~10
Therapeutic Areas
Pulmonology
Stage
Phase 2
Modalities
Antibody-based immunotherapy

Kinevant Sciences General Information

Phase 2 RESOLVE-Lung study of namilumab failed to meet primary endpoint in chronic active pulmonary sarcoidosis. Development discontinued.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
New York, NY
United States

Drug Pipeline

namilumab
Phase 2
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Kinevant Sciences's pipeline data

Book a demo

Key Partnerships

Roivant Sciences

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Kinevant Sciences Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Kinevant Sciences's complete valuation and funding history, request access »